Metraipolis › archive › dc_3b3f4d87faa5

Efficacy and toxicity of hypofractionated radiation therapy for patients with hematologic malignancies: A COVID-era ILROG collaborative report — Europe PMC PMID:41052604

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41052604
DOI
10.1016/j.radonc.2025.111200
License (as archived)
solo-consultazione
Archived
2026-11-09T14:03:16.752Z
SHA-256 of the archived text
fc27ee9da25c52863177583a534f57f328f2befdb5181ce31cfb39bdcb1a9b93
Stable URL of this page
https://metraipolis.com/documento/dc_3b3f4d87faa5

How to cite

Efficacy and toxicity of hypofractionated radiation therapy for patients with hematologic malignancies: A COVID-era ILROG collaborative report — Europe PMC PMID:41052604 — Europe PMC (en), https://europepmc.org/article/MED/41052604 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_3b3f4d87faa5 (Metraipolis archive dc_3b3f4d87faa5, sha256 fc27ee9da25c52863177583a534f57f328f2befdb5181ce31cfb39bdcb1a9b93)
BibTeX
@misc{dc3b3f4d87faa5,
  title = {Efficacy and toxicity of hypofractionated radiation therapy for patients with hematologic malignancies: A COVID-era ILROG collaborative report — Europe PMC PMID:41052604},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41052604},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_3b3f4d87faa5; sha256 fc27ee9da25c52863177583a534f57f328f2befdb5181ce31cfb39bdcb1a9b93},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41052604. Agents can read the archived copy with the MCP tool read_document.